The unexpected SARS-CoV-2 impacted on all aspects of ordinary life especially when it comes to research activities.
To face COVID-19 pandemic, many hospitals have been forced to drastically change their organisation in order to find as much space as possible to accommodate COVID-19 patients; this situation has created an organisational chaos as regards both to therapies for patients not affected by COVID-19 and the stand-by of Clinical Trials (CTs) activities.
EUCROF has released a survey to collect data from EUCROF affiliated member-CROs, to obtain an overview of their contribution to COVID-19 related research, and to collect information on pandemic impact on CTs, measuring the active participation to research activities planned to face coronavirus outbreak.
On January 25, 2021, Applied Clinical Trials published the paper on the survey results that show how EUCROF affiliated member-CROs have worked to create new innovative projects to tackle the pandemic. Moreover, the survey shows that the majority of EUCROF CROs are supporting clinical research activities aimed at developing effective and safe medicines, vaccines, and diagnostics for COVID-19.
Mariangela Lupo, Marta Lettieri and Donato Bonifazi from CVBF are among the authors of the paper that highlights the importance of cooperation between CROs and industry, academia, policy makers, patients’ associations, and society, to find efficient solutions for this and future pandemics.
The article also showed how promptly the respondent CROs have oriented towards research activities to fulfil the current needs which have arisen from the COVID-19 pandemic.
You can read the full article at this link.